CC1083611

CC1083611 is a metabolite of CC-94676 (also known as BMS-986365), an investigational androgen receptor (AR) degrader developed by Celgene (a subsidiary of Bristol Myers Squibb). It is being evaluated in Phase 1 clinical trials for the treatment of metastatic castration-resistant prostate cancer (mCRPC). The parent compound, CC-94676, is a small molecule designed to induce the degradation of the androgen receptor protein, a key driver of prostate cancer progression. CC1083611 is monitored alongside the parent drug to assess safety, tolerability, and pharmacokinetic parameters in patients who have progressed on androgen deprivation therapy and secondary hormonal treatments.